Receptos to move RPC1063 into Phase 3

Receptos (RCPT +22.7%) soars after saying the DMC for its Phase 2/3 trial of RPC1063 in RMS has recommended both the continuation of the Phase 2 portion of the study and the initiation of the Phase 3 component.

The company says data from an interim analysis "support the RPC1063 differentiation profile and [is] consistent with data from prior RPC1063 studies."

Expect top-line data from Phase 2 in mid-2014. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs